Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme

Publisher： John Wiley & Sons Inc

E-ISSN： 1464-410x|115|5|764-771

ISSN： 1464-4096

Source： BJU INTERNATIONAL, Vol.115, Iss.5, 2015-05, pp. : 764-771

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 968-975

John Wiley & Sons Inc

Access to resources Recommend Favorite

Systemic immune‐inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration‐resistant prostate cancer patients

By  

THE PROSTATE, Vol. 78, Iss. 4, 2018-03 ,pp. : 250-256

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical and patient‐reported outcomes of zirconia‐based implant fixed dental prostheses: Results of a prospective case series 5 years after implant placement

By  

CLINICAL ORAL IMPLANTS RESEARCH, Vol. 29, Iss. 1, 2018-01 ,pp. : 91-99

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America

By  

THE PROSTATE, Vol. 75, Iss. 8, 2015-06 ,pp. : 836-844

John Wiley & Sons Inc

Access to resources Recommend Favorite

Metabolic syndrome in castration‐resistant prostate cancer patients treated with abiraterone

By  

THE PROSTATE, Vol. 75, Iss. 12, 2015-07 ,pp. : 1329-1338

John Wiley & Sons Inc

Access to resources Recommend Favorite